Pazopanib plus TGI/CIV for recurrent/refractory rhabdomyosarcoma in children
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (pazopanib and TGI/CIV) for children and teens whose rhabdomyosarcoma has come back or hasn't responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have rhabdomyosarcoma (a type of muscle cancer).
- The cancer must have come back after treatment or not responded to initial chemotherapy.
- You or your child must be between 2 and 18 years old.
- There must be at least one tumor that can be measured on a scan.
- You must be in generally good health, with normal organ function (kidney, liver, heart, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
This trial tests if combining four drugs (pazopanib, trabectedin, ipilimumab, and nivolumab) can help treat soft tissue sarcomas that have come back. It is for children and young adults up to age 30.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Hear when a new Rhabdomyosarcoma, Recurrent, Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.